BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 10908539)

  • 1. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KD
    Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    Clarke C E; Speller J M
    Cochrane Database Syst Rev; 2000; (2):CD000236. PubMed ID: 10796705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pergolide for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M
    Cochrane Database Syst Rev; 2000; (2):CD000235. PubMed ID: 10796704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Speller JM
    Cochrane Database Syst Rev; 2000; 1999(2):CD001514. PubMed ID: 10796800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
    Guttman M
    Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lisuride for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Speller JM
    Cochrane Database Syst Rev; 2000; 1999(2):CD001515. PubMed ID: 10796801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.